Repligen Corporation ( RGEN ) NASDAQ Global Select

Cena: 121.87 ( 4.05% )

Aktualizacja 07-24 22:00
NASDAQ Global Select
Branża: Medical - Instruments & Supplies
Statystyki
Dywidendy
Rekomendacje
Wyceny
Wskaźniki
Analiza techniczna

Notowania:

Opis firmy:

Repligen Corporation opracowuje i komercjalizuje technologie i systemy bioprocesowe do stosowania w procesie produkcji leków biologicznych w Ameryce Północnej, Europie, Azji i Pacyfiku i na arenie międzynarodowej. Oferuje białko ligandów, które są składnikami wiążącymi żywic chromatografii białkowej A powinowactwa; i produkty czynnika wzrostu hodowli komórkowej. Produkty chromatograficzne firmy obejmują kolumny chromatograficzne opakowane Opus, które są wykorzystywane w oczyszczaniu biologii; oraz kolumny Opus mniejszej skali, które są używane w badaniu przesiewowym procesu o wysokiej przepustowości, badaniach walidacji klirensu wirusa i zmniejszaniu walidacji procesów chromatografii. Oferuje również zestawy testowe ELISA; oraz żywice chromatograficzne pod marką Captiva. Ponadto firma zapewnia produkty filtracyjne, takie jak Xcell naprzemienne systemy przepływu stycznego, które są urządzeniami filtracyjnymi stosowanymi w perfuzji i hodowli komórkowej; Płaskie kasety z tangenx, które są stosowane w dalszych procesach biologicznych leków i procesów formułowania; Krosflo styczna filtracja przepływu i systemy filtracji głębokości stycznej; Produkty laboratoryjne i dializacyjne Spectra/Por oraz dynamiczna systemy dializy Spectroflo; i Proconnex Pojedyncze puste światłowód. Ponadto zapewnia produkty analityczne procesów, takie jak systemy spektroskopii nachylenia pod markami Solovpe, FlowVPE i FlowVPX. Firma sprzedaje swoje produkty do dzielnic nauk przyrodniczych, biofarmaceutycznych i diagnostycznych; badacze laboratoryjni; oraz organizacje produkcyjne kontraktowe. Repligen Corporation ma umowy o współpracy z białkami Navigo GmbH w celu opracowania ligandów wielu powinowactwa. Repligen Corporation został zarejestrowany w 1981 roku i ma siedzibę w Waltham, Massachusetts.

Informacje o spółce:
Sektor: Zdrowie
Branża: Medical - Instruments & Supplies
Zatrudnienie: 1 783
Giełda: NASDAQ Global Select
Ilość akcji w obrocie: 93.19
Ilość akcji: Brak danych
Debiut giełdowy: 1986-04-29
WWW: https://www.repligen.com
CEO: Mr. Olivier Loeillot
Adres: Building 1
Siedziba: 02453 Waltham
ISIN: US7599161095
Wskaźniki finansowe
Kapitalizacja (USD) 6 847 034 397
Aktywa: 2 830 644 000
Cena: 121.87
Wskaźnik Altman Z-Score: 7.1
Stabilny (niskie ryzyko bankructwa)
Dywidenda: 0
P/E: -290.2
Ilość akcji w obrocie: 93%
Średni wolumen: 792 998
Ilość akcji 56 183 100
Wskaźniki finansowe
Przychody TTM 616 033 000
Zobowiązania: 813 958 000
Przedział 52 tyg.: 102.97 - 182.52
Piotroski F-Score: 4
Umiarkowany (średnia jakość finansowa)
EPS: -0.4
P/E branży: 29.9
Beta: 0.959
Raport okresowy: 2025-07-29
WWW: https://www.repligen.com
Zarząd
Imie i Nazwisko Stanowisko Wynagrodzenie Rok urodzenia
Mr. Anthony J. Hunt Chief Executive Officer & Director 885 000 1964
Mr. James R. Bylund Chief Operating Officer 472 181 1964
Mr. Ralf Kuriyel Senior Vice President of Research & Development 401 743 1958
Ms. Christine Gebski Senior Vice President of Filtration & Chromatography 396 094 1968
Mr. Jason K. Garland Chief Financial Officer & Chief Compliance Officer 282 987 1974
Mr. Olivier Loeillot President & Chief Commercial Officer 1 488 462 1970
Mr. Neil Whitfield Vice President & Global Head of Sales 0 0
Mr. Keith Lee Robinson Chief Information Officer 0 0
Ms. Kimberly A. Cornwell General Counsel & Global Head of Legal 0 0
Ms. Sondra S. Newman Global Head of Investor Relations 0 0
Lista ETF z ekspozycją na akcje Repligen Corporation
Symbol ETF Ilość akcji Wartość
IJH 1 744 432 217 059 612
VB 1 342 549 158 514 760
VBK 739 862 87 355 506
MDY 403 383 50 306 161
IBB 339 128 42 197 668
FBT 255 148 31 748 065
SPMD 236 780 29 502 540
IWR 188 677 23 477 042
IJJ 172 371 21 448 102
VHT 166 829 19 697 500
SCHM 138 465 17 650 133
IJK 129 602 16 126 357
XT 112 067 13 944 453
DFAS 105 880 13 496 523
IWD 105 542 13 132 596
SCHG 79 716 10 158 339
IVOO 77 478 9 147 827
IWS 68 892 8 572 230
2B78.DE 66 857 8 319 074
HEAL.L 66 857 8 319 074
DRDR.L 66 857 8 319 074
DFAC 65 745 8 380 515
ITOT 63 831 7 942 528
MDYV 52 283 6 551 506
SCHX 51 325 6 542 397
PBE 48 436 6 174 136
IWP 43 605 5 425 760
IWB 38 562 4 798 225
BBH 36 948 4 690 918
IUSN.DE 35 442 4 410 079
WSML.L 35 442 4 410 079
WLDS.L 35 442 4 410 079
FNDA 35 288 4 390 614
MDYG 32 575 4 060 256
CSMD 32 441 4 135 254
IWF 30 778 3 829 708
CSUSS.MI 29 949 3 726 585
SXRG.DE 29 949 3 726 585
CUSS.L 29 949 3 726 585
CUS1.L 29 949 3 726 585
IYH 29 006 3 609 185
JHMM 28 393 3 796 711
VONV 25 685 3 032 627
BBMC 24 730 3 075 917
IUSV 24 622 3 063 741
ESML 24 363 3 105 551
TMSL 22 974 2 916 779
FHLC 22 793 2 893 799
IVOV 22 290 2 631 780
PRFZ 21 606 2 754 116
FSMD 21 383 2 714 785
IVOG 18 235 2 153 006
IUSG 18 006 2 240 540
DFUV 17 952 2 288 341
IWV 14 892 1 853 031
WSCR.L 13 733 1 750 601
ONEQ 13 511 1 722 247
DFUS 13 383 1 705 931
ESGV 12 194 1 551 564
SMMD 12 183 1 552 967
SMLF 10 916 1 358 320
VONG 9 845 1 162 399
JMEE 9 415 1 171 037
ISCG 8 913 1 108 989
SPTM 8 841 1 100 088
VONE 8 538 1 008 081
DFAU 8 468 1 079 415
TSPA 7 965 940 427
PTMC 7 700 981 519
NUSC 7 148 1 177 561
XMC.TO 6 804 1 155 149
QVMM 6 150 783 940
XJH 5 673 723 137
IQSM 5 502 701 339
IJH.AX 5 352 1 022 221
EQAL 4 805 612 493
XMH.TO 4 484 761 271
VTHR 4 342 512 659
AVUS 4 118 524 921
ISCV 4 100 510 134
EZM 3 958 504 724
SCHK 3 925 488 191
DFSU 3 605 459 529
ETHO 3 586 457 107
FMED 3 000 380 880
SIXL 2 979 0
ISCB 2 528 314 595
PEXL 2 519 321 096
XUU.TO 2 376 422 532
XEQT.TO 2 317 393 336
IYY 2 275 283 110
QGRO 2 229 378 205
DCOR 2 150 274 060
MVV 2 061 262 715
TILT 1 824 236 791
GUSA 1 775 226 259
RWK 1 648 210 070
XAW.TO 1 436 243 730
PTL 1 374 175 143
JHML 1 209 161 667
HELX 1 061 130 874
MIDU 952 120 865
MMSC 891 110 867
V3AL.L 766 90 441
V3AA.L 766 90 441
GVUS 593 75 589
BMED 533 66 284
AVLC 517 65 901
XBAL.TO 357 63 481
WDNA.L 352 43 419
WBIO.L 352 43 419
UMDD 340 43 339
XUH.TO 340 42 254
SPGM 297 37 004
STXM 277 35 309
USUE.DE 266 33 950
USFM.L 266 33 950
FNDB 238 29 602
R1VL.L 216 26 876
VLU 213 26 593
WDNA 162 20 658
STXG 144 18 355
MIDE 140 17 845
AVSU 116 14 786
R1GR.L 106 13 189
ONEO 102 12 672
GGUS 100 12 747
AMEW.DE 35 4 543
CW8.PA 35 4 543
CW8G.L 35 4 543
CW8U.L 35 4 543
XTR.TO 14 1 809
JCTR 13 1 616
AVMC 9 1 147
MMTM 6 745
PZW.TO 0 0
FTLS -29 399 0
Wiadomości dla Repligen Corporation
Tytuł Treść Źródło Aktualizacja Link
Repligen's Q4 Earnings Beat Estimates, Revenues In Line RGEN reports decent fourth-quarter results and issues guidance for 2025. zacks.com 2025-02-21 13:35:30 Czytaj oryginał (ang.)
Repligen Corporation (RGEN) Q4 2024 Earnings Call Transcript Repligen Corporation (NASDAQ:RGEN ) Q4 2024 Earnings Call Transcript February 20, 2025 8:30 AM ET Company Participants Sondra Newman - Global Head of Investor Relations Olivier Loeillot - President and Chief Executive Officer Jason Garland - Chief Financial Officer Conference Call Participants Dan Arias - Stifel Rachel Vatnsdal - J.P. Morgan Puneet Souda - Leerink Partners Matt Larew - William Blair & Company Jacob Johnson - Stephens Inc. Conor McNamara - RBC Capital Markets Matt Hewitt - Craig Hallum Subbu Nambi - Guggenheim Securities Justin Bowers - Deutsche Bank Paul Knight - KeyBanc Capital Doug Schenkel - Wolfe Research Operator Good day, ladies and gentlemen. seekingalpha.com 2025-02-20 16:53:12 Czytaj oryginał (ang.)
Repligen Q4 Earnings Momentum Highlights Market Growth, Issues Strong 2025 Outlook Repligen Corp RGEN released its fourth-quarter adjusted EPS of 44 cents on Tuesday, down from 48 cents a year ago but beating the consensus of 41 cents. benzinga.com 2025-02-20 16:00:57 Czytaj oryginał (ang.)
Repligen's Q4 Slightly Tops Expectations Repligen (RGEN 7.92%), a bioprocessing technology company, announced its earnings for the fourth quarter on Feb. 20. Its adjusted earnings per share (EPS) of $0.44 exceeded analysts' consensus estimate of $0.41, but fell year over year. fool.com 2025-02-20 13:25:28 Czytaj oryginał (ang.)
Repligen (RGEN) Beats Q4 Earnings Estimates Repligen (RGEN) came out with quarterly earnings of $0.44 per share, beating the Zacks Consensus Estimate of $0.41 per share. This compares to earnings of $0.33 per share a year ago. zacks.com 2025-02-20 11:45:22 Czytaj oryginał (ang.)
Repligen to Report Fourth Quarter and Full Year 2024 Financial Results Webcast and Conference Call to Be Held Thursday, February 20, 2025, at 8:30 a.m. ET Webcast and Conference Call to Be Held Thursday, February 20, 2025, at 8:30 a.m. ET globenewswire.com 2025-02-11 09:30:00 Czytaj oryginał (ang.)
HRMY vs. RGEN: Which Stock Is the Better Value Option? Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Harmony Biosciences Holdings, Inc. (HRMY) and Repligen (RGEN). But which of these two stocks presents investors with the better value opportunity right now? zacks.com 2025-01-30 14:41:12 Czytaj oryginał (ang.)
Repligen (RGEN) Surges 3.7%: Is This an Indication of Further Gains? Repligen (RGEN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term. zacks.com 2025-01-29 06:20:12 Czytaj oryginał (ang.)
Repligen price target lowered to $180 from $240 at H.C. Wainwright H.C. Wainwright lowered the firm's price target on Repligen to $180 from $240 and keeps a Buy rating on the shares. The firm says the company could generate solid top- and bottom-line growth in the coming year. It lowered the price target saying Repligen's "explosive growth" of the COVID-19 years is no longer evident, but notes that the company's risk profile and overall positioning remain attractive. https://thefly.com 2025-01-23 08:06:48 Czytaj oryginał (ang.)
HRMY or RGEN: Which Is the Better Value Stock Right Now? Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Harmony Biosciences Holdings, Inc. (HRMY) and Repligen (RGEN). But which of these two companies is the best option for those looking for undervalued stocks? zacks.com 2025-01-14 14:40:19 Czytaj oryginał (ang.)
Repligen Corporation to Present at 43rd Annual J.P. Morgan Healthcare Conference WALTHAM, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will participate in the 43rd Annual J.P. Morgan Healthcare Conference, being held January 13 – 16 in San Francisco. Olivier Loeillot, President and Chief Executive Officer, will present an overview of the company on Tuesday, January 14 at 1:30 p.m. PT. globenewswire.com 2025-01-07 09:30:00 Czytaj oryginał (ang.)
Repligen Launches the CTech™ SoloVPE® PLUS System WALTHAM, Mass., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the commercial launch of its CTech™ SoloVPE® PLUS System, the most advanced UV-based Variable Pathlength Technology system now available to biopharmaceutical manufacturers. globenewswire.com 2025-01-06 09:30:00 Czytaj oryginał (ang.)
BioLife Solutions Appoints Tony J. Hunt to its Board of Directors BOTHELL, Wash. , Dec. 16, 2024 /PRNewswire/ -- BioLife Solutions , Inc. (Nasdaq: BLFS ) ("BioLife" or the "Company"), a leading developer and supplier of bioproduction tools and services for the cell and gene therapy (CGT) market, announces the appointment of Tony J. prnewswire.com 2024-12-16 10:11:00 Czytaj oryginał (ang.)
Repligen (RGEN) Up 3.2% Since Last Earnings Report: Can It Continue? Repligen (RGEN) reported earnings 30 days ago. What's next for the stock? zacks.com 2024-12-12 14:36:22 Czytaj oryginał (ang.)
Repligen Announces Publication of the Company's 2023 Corporate Sustainability Report WALTHAM, Mass., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the digital publication of its 2023 Corporate Sustainability Report and related reporting framework disclosures. Themed “Advancing Impacts”, this newly reformatted report streamlines the company's progress in advancing our sustainability strategy across six key impact areas: Products & Packaging, Operations, Talent, Supply Chain, Communities and Partnerships & Pathways. Also included in the 2023 Sustainability Report are detailed disclosures aligned with four key reporting frameworks: the Global Reporting Initiative (GRI) Standards, Sustainability Accounting Standards Board (SASB), United Nations Sustainable Development Goals (UN SDGs) and Task Force on Climate-Related Disclosures (TCFD). globenewswire.com 2024-12-12 09:30:00 Czytaj oryginał (ang.)
Repligen Launches Novel AVIPure® dsRNA Resin in OPUS® Pre-packed Columns Breakthrough Innovation for the Purification of mRNA Therapeutics and Vaccines Breakthrough Innovation for the Purification of mRNA Therapeutics and Vaccines globenewswire.com 2024-12-09 09:30:00 Czytaj oryginał (ang.)
Repligen Corporation (RGEN) Q3 2024 Earnings Call Transcript Repligen Corporation (NASDAQ:RGEN ) Q3 2024 Results Earnings Conference Call November 12, 2024 8:30 AM ET Company Participants Sondra Newman - Vice President, Global Head of Investor Relations Olivier Loeillot - President and Chief Executive Officer Jason Garland - Chief Financial Officer Conference Call Participants Dan Leonard - UBS Dan Arias - Stifel Rachel Vatnsdal - J.P. Morgan Puneet Souda - Leerink Partners Matt Larew - William Blair & Company Jacob Johnson - Stephens Inc. Conor McNamara - RBC Capital Markets Evan Stock - Wells Fargo Matthew Hewitt - Craig-Hallum Subbu Nambi - Guggenheim Securities Justin Bowers - Deutsche Bank Paul Knight - KeyBanc Capital Matt Stanton - Jefferies LLC Operator Good day, ladies and gentlemen, and welcome to Repligen Corporation's Third Quarter of 2024 Earnings Conference Call. seekingalpha.com 2024-11-12 17:07:27 Czytaj oryginał (ang.)
Repligen Beats on Q3 Earnings & Sales, Narrows '24 Sales View RGEN reports better-than-expected third-quarter results. While management lowers its guidance for 2024 total sales, it raises the same for EPS. zacks.com 2024-11-12 16:40:33 Czytaj oryginał (ang.)
Repligen Q3 Earnings Beat Expectations, Highlights Improving Market Conditions, Analyst Says Well-Positioned For Long-Term Growth Repligen Corp RGEN released on Tuesday third-quarter adjusted EPS of 43 cents, up from 23 cents a year ago, beating the consensus of 33 cents. benzinga.com 2024-11-12 15:19:20 Czytaj oryginał (ang.)
Repligen (RGEN) Q3 Earnings and Revenues Beat Estimates Repligen (RGEN) came out with quarterly earnings of $0.43 per share, beating the Zacks Consensus Estimate of $0.34 per share. This compares to earnings of $0.23 per share a year ago. zacks.com 2024-11-12 12:05:23 Czytaj oryginał (ang.)
Repligen Corporation's Earnings Preview: Expensive With Mixed Growth Prospects Repligen Corporation is a bioprocessing technology company focusing on process intensification, purification, and fluid management, with strategic acquisitions to enhance its capabilities. Though integration risks remain, RGEN's recent acquisition of Tantti Laboratory aims to bolster its chromatography and biomolecule purification capacities. The potential acquisition of Maravai LifeSciences could impact RGEN's future growth, but past failed attempts and divestment plans add uncertainty. seekingalpha.com 2024-11-12 08:36:27 Czytaj oryginał (ang.)
Repligen Corporation to Present at Upcoming Investor Conferences WALTHAM, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be presenting at three upcoming investor conferences. globenewswire.com 2024-11-05 09:30:00 Czytaj oryginał (ang.)
Repligen (RGEN) Earnings Expected to Grow: What to Know Ahead of Q3 Release Repligen (RGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. zacks.com 2024-10-22 15:05:49 Czytaj oryginał (ang.)
Peptide Therapeutics Industry Report 2024, Featuring Profiles of 30+ Leading Players Including PeptiDream, PolyPeptide, Repligen, X-GEN Pharmaceuticals, Zydus Cadila and More Dublin, Oct. 14, 2024 (GLOBE NEWSWIRE) -- The "Peptide Therapeutics - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering. The global market for Peptide Therapeutics was estimated at US$42.1 Billion in 2023 and is projected to reach US$56.2 Billion by 2030, growing at a CAGR of 4.2% from 2023 to 2030. The development of peptide therapeutics has been greatly accelerated by technological advances, enabling the creation of more stable, potent, and targeted therapies. Peptides, which are naturally occurring biological molecules, serve as signaling agents in the body and have high specificity for their targets, making them attractive candidates for therapeutic development. Innovations in peptide engineering have led to the development of modified peptides that resist enzymatic degradation, improve bioavailability, and have extended half-lives, allowing for less frequent dosing. globenewswire.com 2024-10-14 15:15:00 Czytaj oryginał (ang.)
Repligen Opens Training & Innovation Center to Elevate Customer Experience WALTHAM, Mass., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the grand opening of its Repligen Training & Innovation Center (“RTIC”) at its Waltham headquarters. globenewswire.com 2024-09-24 11:30:00 Czytaj oryginał (ang.)
Repligen Corporation to Present at Wells Fargo Healthcare Conference WALTHAM, Mass., Aug. 23, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be presenting at the Wells Fargo Healthcare Conference being held September 4-6 in Boston. Olivier Loeillot, President and Chief Executive Officer will participate in an analyst-led discussion on Friday, September 6, at 8:45 a.m. ET. globenewswire.com 2024-08-23 11:30:00 Czytaj oryginał (ang.)
Exclusive: Repligen in bid for reagent vendor Maravai, sources say Repligen , a provider of drug manufacturing equipment, has approached Maravai LifeSciences Holdings , a vaccine capping reagent vendor that has a market value of $2.2 billion, with an acquisition offer, people familiar with the matter said on Friday. reuters.com 2024-08-16 15:46:16 Czytaj oryginał (ang.)
Here's Why Shares in This Hot Healthcare Stock Surged This Week A far larger peer backs up Repligen's market commentary. Bioprocessing customers are working through inventory, and orders growth is bouncing back. fool.com 2024-08-02 11:09:48 Czytaj oryginał (ang.)
These Analysts Revise Their Forecasts On Repligen Following Q2 Results Repligen Corporation RGEN reported in-line earnings for its second quarter on Tuesday. benzinga.com 2024-07-31 18:50:50 Czytaj oryginał (ang.)
Repligen's (RGEN) Q2 Earnings & Revenues Meet Estimates Repligen's (RGEN) second-quarter earnings and revenues match estimates. The company narrows its revenue guidance for 2024. zacks.com 2024-07-31 15:51:16 Czytaj oryginał (ang.)
Repligen Corporation (RGEN) Q2 2024 Earnings Call Transcript Repligen Corporation [RGEN] Q2 2024 Earnings Conference Call July 30, 2024 8:30 AM ET Company Participants Tony Hunt - CEO Jason Garland - CFO Olivier Loeillot - President & CCO Sondra Newman - IR Conference Call Participants Rachel Vatnsdal - J.P. Morgan Dan Arias - Stifel Jacob Johnson - Stephens Inc. Puneet Souda - Leerink Partners Justin Bowers - Deutsche Bank Matt Larew - William Blair Conor McNamara - RBC Capital Markets Dan Leonard - UBS Paul Knight - KeyBanc Matt Hewitt - Craig-Hallum Capital Group Matt Stanton - Jefferies Tom DeBourcy - Nephron Research Subbu Nambi - Guggenheim Securities Operator Good day, ladies and gentlemen, and welcome to Repligen Corporation's Second Quarter of 2024 Earnings Conference Call. seekingalpha.com 2024-07-30 19:03:09 Czytaj oryginał (ang.)
Repligen Lowers Guidance On China Weakness, Analyst Expects Tuesday, Repligen Corporation RGEN reported second-quarter sales of $154.1 million, almost in line with the consensus estimate of $154.12 million. benzinga.com 2024-07-30 16:01:42 Czytaj oryginał (ang.)